fda warning bpc 157 not approved peptide safety For anyone interested in how the true approval process moves and works: Yesterday (July 23, 2026) the FDA's Pharmacy Compounding Advisory Committee voted to recommend four peptides for the 503A Bulks List HARDCORE SERIES Packages:3 Pack TIRZEPATIDE

fda warning bpc 157 not approved peptide safety For anyone interested in how the true approval process moves and works: Yesterday (July 23, 2026) the FDA's Pharmacy Compounding Advisory Committee voted to recommend four peptides for the 503A Bulks List HARDCORE SERIES Packages:3 Pack TIRZEPATIDE

TIRZEPATIDE

Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H

HARDCORE SERIES

Packages:3 Pack

The most common sites for tirzepatide are: Abdomen (2 inches away from the navel, rotating sides) Front of thighs (upper third, alternating legs) Back of upper arms (harder to self-administer) Rotate injection sites with every dose